VINBLASTINE SULFATE 1 Mg/Ml Solution for Inj/Inf

País: Irlanda

Idioma: anglès

Font: HPRA (Health Products Regulatory Authority)

ingredients actius:

VINBLASTINE SULFATE

Disponible des:

Hospira UK Limited

Codi ATC:

L01CA01

Designació comuna internacional (DCI):

VINBLASTINE SULFATE

Dosis:

1 Mg/Ml

formulario farmacéutico:

Solution for Inj/Inf

tipo de receta:

Product subject to prescription which may not be renewed (A)

Área terapéutica:

Vinca alkaloids and analogues

Estat d'Autorització:

Authorised

Data d'autorització:

1990-10-15

Informació per a l'usuari

0004120-MC03
Black:
COMPONENT SPECIFICATION
Item number:
0004120-MC03
Request number:
PAR-2016-0004120
Country:
Ireland
I have checked this artwork against the 
registered text including spelling, layout, size, 
colours, registration numbers and scientific 
equations, the name and address and 
trademarks. Also for any possible changes to 
related items.
This artwork is in conformance with the 
Marketing Authorisation and can now proceed 
to the printing stage.
Previous Item Number:
Signed:
Date:
VERSION 1
Technician: COD
Date: 09/Jun/16
VERSION 2
Technician: BC
Date: 08/Sep/16
VERSION 3
Technician: BR
Date: 13/Sep/16
VERSION 4
Technician: CS
Date: 17/Oct/16
VERSION 5
Technician: XX
Date: 
dd/mmm/yy
VERSION 6
Technician: XX
Date: dd/mmm/yy
VERSION 7
Technician: XX
Date: dd/mmm/yy
VERSION 8
Technician: XX
Date: dd/mmm/yy
VERSION 9
Technician: XX
Date: dd/mmm/yy
VERSION 10
Technician: XX
Date: dd/mmm/yy
OI template:
Amalia version:
Mulgrave version:
SVI007
1
n/a
Dimensions:
Container(s):
Supplier:
Stock:
Folded dimensions:
Printed both sides:
Perforated:
118 x 570 mm (20 panels)
vial
EU Packing Centre
40 gsm
28.5 x 118 mm
Yes
No
Pharma code:
Pharma code length:
Supplier Code:
n/a
n/a
n/a
COLOURS
REQUESTER
PACKAGE LEAFLET: 
INFORMATION FOR THE USER
VINBLASTINE SULFATE 1 MG/ML SOLUTION FOR INJECTION OR INFUSION
Vinblastine Sulfate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE.
•  Keep this leaflet. You may need to read it again.
•  If you have any further questions, ask your doctor.
•   If any of the side effects gets serious, or if you notice any
side effects not
listed in this leaflet, please tell your doctor.
IN THIS LEAFLET:
1.  What Vinblastine Sulfate is and what it is used for
2.  Before you use Vinblastine Sulfate
3.  How to use Vinblastine Sulfate
4.  Possible side effects
5.  How to store Vinblastine Sulfate
6.  Contents of the pack and other information
1.  WHAT VINBLASTINE SULFATE IS AND WHAT IT IS USED FOR
Vinblastine Sulfate is an a

Fitxa tècnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Vinblastine Sulfate 1mg/ml Solution for Injection or Infusion.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml contains 1.0 mg of Vinblastine Sulfate.
Each 10ml vial contains 10 mg of Vinblastine Sulfate.
Excipient(s) with known effect: Each 10ml vial contains approximately
35mg (1.5mmol) sodium
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection/infusion
A clear, colourless, sterile solution.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Vinblastine Sulfate is used either alone or in combination with other
neoplastic agents, in the treatment of Hodgkin's
Disease (Stages III and IV); lymphocytic lymphoma (nodular and
diffuse, poorly and well differentiated); histiocytic
lymphoma; advanced stages of mycosis fungoides; advanced carcinoma of
the testis; Kaposi's sarcoma and Letterer-
Siwe disease (histocytosis X).
Vinblastine Sulfate may be used in the treatment of choriocarcinoma
resistant to other
chemotherapeutic agents; carcinoma of the breast, unresponsive to
appropriate endocrine surgery and hormonal
therapy.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
IN CASE OF MISTAKEN ADMINISTRATION BY THE INTRATHECAL ROUTE, SEE
SECTION 4.4.
It is recommended to infuse Vinblastine Sulfate over 5 to 10 minutes
after dilution in Sodium Chloride 0.9% to a final
volume of 50 ml to 100 ml with a final concentration between 0.04 and
0.4mg/ml.
Alternatively, Vinblastine Sulfate may be injected directly into a
vein over about one minute.
Syringes containing this product should be overlabelled with the
warning label provided:
'FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN BY OTHER ROUTES'. DOSAGE
Vinblastine sulfate is given intravenously at weekly intervals
according to the needs of the patient.
Therapy is initiated
by a single intravenous dose in accordance with the following dosage
table, and white blood cell counts should be
made to determine the sensitivity of the patient to vinblastine.
FOR INTRAVENOUS USE ONLY.
FA